Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Waldenstrom Macroglobulinemia 1Multiple Myeloma 1Lymphoma, Mantle-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Hairy Cell 1

Interventions

Cyclophosphamide 139Vincristine 105Rituximab 100Doxorubicin 87Etoposide 79Prednisone 69Cytarabine 67Filgrastim 63Specimen Handling 62Methotrexate 60Biopsy 60Magnetic Resonance Spectroscopy 51fludarabine phosphate 50Dexamethasone 47Radiotherapy 43Peripheral Blood Stem Cell Transplantation 35Leucovorin 35Bortezomib 32Prednisolone 28Mercaptopurine 27merphos 24Ifosfamide 24Asparaginase 24Daunorubicin 23Lenalidomide 22ibrutinib 21fludarabine 21Calcium Dobesilate 21pegaspargase 19Alemtuzumab 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × ON 01910 × Lymphoid × Clear all
NCT00861510 2019-12-03

A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
16 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Hairy Cell, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡